A Project of The Annenberg Public Policy Center

Azar, Trump Mislead on FDA’s Hydroxychloroquine Decision

Azar, Trump Mislead on FDA’s Hydroxychloroquine Decision

At the White House, the Health and Human Services secretary left the misleading impression that the FDA’s decision to revoke its emergency use authorization of hydroxychloroquine and chloroquine for COVID-19 “removes a potential barrier” and makes it easier to access the drugs. The FDA’s action does the opposite.

Trump’s Faulty Malaria-Coronavirus Connection

Trump’s Faulty Malaria-Coronavirus Connection

Falsely citing “studies,” President Donald Trump has suggested that there are few novel coronavirus cases in “malaria countries” because of the use of the antimalarial drug hydroxychloroquine. But no such studies exist, and the drug is not widely used for malaria in much of the world.